Alligator Bioscience Raises SEK 19 Million Through TO 14 Warrant Exercise

An announcement from Alligator Bioscience AB ( (SE:ATORX) ) is now available.

Alligator Bioscience AB has completed the exercise period for its TO 14 warrants, issued in connection with a 2025 rights issue, resulting in 93,589,862 warrants being converted into the same number of new ordinary shares at SEK 0.20 each, an exercise rate of about 38 percent. The transaction provides the company with roughly SEK 19 million in gross proceeds, or about SEK 12 million net after issue costs and repayments under a renegotiated loan, increases the share count to 628,106,848 and share capital to SEK 125.6 million, and results in approximately 15 percent dilution for shareholders who did not participate.

Following registration with the Swedish Companies Registration Office, the exercised TO 14 warrants will be replaced by ordinary shares, consolidating the enlarged capital structure. The outcome modestly strengthens Alligator Bioscience’s financial position as it advances its immuno-oncology pipeline, while existing investors absorb a notable but expected level of dilution linked to the prior rights issue financing package.

The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.16 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.

More about Alligator Bioscience AB

Alligator Bioscience AB is a Swedish biotechnology company specializing in clinical-stage, tumor-directed antibody drugs focused on the CD40 receptor in immuno-oncology. Its lead drug candidate, mitazalimab, is ready for Phase 3 development and has shown strong 30‑month survival data in metastatic pancreatic cancer, and the company is listed on Nasdaq Stockholm and headquartered in Lund.

YTD Price Performance: -44.94%

Average Trading Volume: 5,340,268

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK98.89M

See more data about ATORX stock on TipRanks’ Stock Analysis page.